JUN and non-small cell lung carcinoma: PD-L1 and c-Jun levels were significantly increased, while HDAC3 levels were significantly decreased in the cisplatin-resistant NSCLC tissues compared with the cisplatin-sensitive tumor tissues (Fig. 7a and b).